On Thursday, the FDA granted full approval to Humacyte, Inc.’s (NASDAQ:HUMA) Symvess (acellular tissue-engineered vessel-tyod) use in adults as a vascular conduit for extremity arterial injury when ...
Are you a houseplant lover? Can’t get enough green, leafy plants? We have some exciting news for you. A French startup called Neoplants recently launched a bioengineered houseplant designed to clean ...
An investigational product called Acellular Tissue Engineered Vessel demonstrated superior hemodialysis vascular access outcomes compared with AVFs in a phase 3 trial. A bioengineered human tissue ...
The FDA on Friday approved acellular tissue engineered vessel (Symvess), an off-the-shelf product for treating vascular trauma in the extremities of adults. The one-time, single-use therapy -- the ...
The Mayo Foundation for Medical Education and Research, the nonprofit parent entity of the Mayo Clinic, is a worldwide research powerhouse that is assigned scores of U.S. patents each year. Mayo ...
A new type of bioengineered blood vessel showed strong results in treating severe vascular injuries, potentially offering vascular surgeons a better alternative to synthetic grafts when patients' ...
The Grande Ronde Hospital (GRH) Wound Clinic, located at 700 Sunset Dr., Suite F, has experienced significant growth over the past 15 years, evolving from a single-room clinic in the SurgiCenter that ...
– Patent covers esophagus produced using Humacyte’s proprietary bioengineered regenerative tissue platform, designed for implant in patients with damaged esophagus – – Patent provides coverage into ...
In a study published in Advanced Materials on July 22, a team led by Dr. Zhong Chao and Dr. An Bolin from the Shenzhen Institute of Advanced Technology of the Chinese Academy of Sciences, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback